SCHEMBL21626828

SCHEMBL21626828

COc1cc(OC)c(F)c(C(O)c2c[nH]c3ncc(Br)cc23)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.38
FGFR1 P11362 2/20 0.38
KDR P35968 2/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
INSR P06213 1/20 0.38
CDK1 P06493 1/20 0.38
FES P07332 1/20 0.38
IGF1R P08069 1/20 0.38
ROS1 P08922 1/20 0.38
PHKG2 P15735 1/20 0.38
FER P16591 1/20 0.38
FLT1 P17948 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27893617 0.85 BRD4 (0.34) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL10260194 0.84 DYRK1A (0.40) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL1357872 0.84 MET (0.40) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL859235 0.81 BRAF (0.35) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL858321 0.80 BRAF (0.37) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL21626895 0.79 CHEK1 (0.32) FGFR1KDRAURKBKITNTRK1
SCHEMBL10268093 0.79 DYRK1A (0.40) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL21626843 0.78 F2 (0.39) DYRK1AKITMAP3K11AAK1LRRK2
SCHEMBL859205 0.78 MTNR1A (0.39) DYRK1AFGFR1KDRPLK4AURKA
SCHEMBL858698 0.78 JAK2 (0.39) DYRK1AFGFR1KDRPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322760-A1 CRYSTAL FORM OF AZAINDOLE DERIVATIVE AND USE THEREOF WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) 2023-10-12 US disclosed
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) 2021-08-19 US disclosed
EP-3825314-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR Medshine Discovery Inc. (CN) 2021-05-26 EP disclosed
WO-2020015744-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR 南京明德新药研发有限公司 2020-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322760-A1 CRYSTAL FORM OF AZAINDOLE DERIVATIVE AND USE THEREOF AZI2, GDI2, GDI1 DYRK1A 1872/4885FGFR1 4731/4885KDR 4046/4885
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR MET, FGFR1, FGFR2 DYRK1A 542/4885FGFR1 2/4885KDR 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.